COMPARATIVE STUDY OF ANTIMICROBIAL EFFICACY OF AZITHROMYCIN AND CEFIXIME AGAINST SALMONELLA TYPHI INFECTION

Raj Kumar Thapa¹, Sagar Shrestha^{2*}

1* Ph. D Scholar, Mewar University, Rajasthan, India
^{2*} S R Pharmaceuticals Pvt Ltd, Kathmandu
* Corresponding author <u>trichan2015@gmail.com</u>

ABSTRACT

Introduction: Enteric fever is systemic infection caused by the *Salmonella enteric serovars typhi* and *para typhi* A B and C. It is the significant cause of morbidity and mortality. It occurs in all parts of the world where water supplied and sanitation is substandard. Annually, it is estimated that more than 10 million cases and 100000 deaths are caused by typhoid fever. Regarding to the strains, a high prevalence of *S. typhi* and *S. paratyphi*. A strains in Nepal that showed resistance against the quinolone nalidixic acid (MIC> 256 mcg/ml with a corresponding decreased susceptibility against fluoroquinolones such as ciprofloxacin (MIC>0.125 mcg/ml)

Objectives: The main objective of study was to compare the efficacy of Azithromycin and Cefixime in treatment of typhoid fever.

Methodology: The in vitro antibacterial activity of azithromycin and Cefixime against 4 isolated colonies of *Salmonella typhi* from reference of *salmonella typhi* ATCC no. 14028 and blood culture isolates from three different hospitals was evaluated by disc diffusion (well) method. 0.25 ppm, 0.5 ppm, 4 ppm, 8 ppm, 32 ppm, 128 ppm concentration of both Azithromycin and Cefixime was used. The zone of inhibition was measured and data was analyzed using Excel.

Results: In all isolates of *Salmonella typhi*, the zone of inhibition shown by both Azithromycin and Cefixime is same at low concentration (0.25ppm, 0.5ppm) but with increasing in concentration there is increase in difference in zone of inhibition shown by them. The zone of inhibition shown by Cefixime is greater in high concentration as compared to zone of inhibition shown by Azithromycin

Conclusion: Our result indicate Cefixime is better than Azithromycin in therapeutic option for enteric fever.

Nepal, Salmonella typhi, Azithromycin, Cefixime, Antibiotic resistance

INTRODUCTION

Enteric fever is systemic infection caused by the *Salmonella enteric serovars typhi* and *para typhi A, B and C.* It is the significant cause of morbidity and mortality¹. It occurs in all parts of the world where water supplied and sanitation is substandard. Annually, it is estimated that more than 10 million cases and 100000 deaths are caused by Typhoid fever. ^{2, 3, 4}

In 2008, the WHO recommended in using the vaccines for enteric fever as to control and outbreak the enteric fever as an endemic disease. As per one study more than 190,000 patients were died of enteric fever in 2010 deaths.⁵ The incidence of enteric fever is higher than 7.6 per 1000 per year (India).Case fatality rate due to typhoid is varied between 1.1 and 2.5%. It is one of the killer diseases in Nepal.⁶

In Nepal, all the enteric fever related data has been generating from the Kathmandu valley instead of remote area of Nepal as about 90% of the Nepali population lives outside the region or in rural areas [7]. In summer season most of the hospital will be occupied with the patients of enteric fever. Even emergency department will be also being occupied with it. Children and adult are almost equally affected by this leading febrile bacterial disease.^{8,9}

Because of the lack of proper treatment guidelines and poor surveillance of DDA to retails shop and Nursing home, most of the antibiotics are resistance (resistance of *Salmonella* to antibiotics as well).^{10,11} Still there is no reserved antibiotic list of antibiotics in Nepal as Azithromycin and Ceftriaxone are the drug of choices for enteric fever. Now time has come to find the next generation of drugs as option.^{12, 13}

In early 1990s, Chloramphenicol, Ampicillin and Cotrimoxazole were being used as the first line treatment for enteric fever. Unfortunately, *S. typhi* resistant to all first line drugs as mentioned. Fluoroquinolone were widely regarded as the most effective drug for the treatment of typhoid fever. [14]. Ciprofloxacin and Ofloxacin were being still used but also developing resistance or reduced susceptibility to fluoroquinolones.^{15,16,17} A review conducted by Thapa and Khanal¹⁸ the treatment paradigm is shifted to third generation cephalosporin. Another research conducted by the same authors Ceftriaxone had more cure rate in comparison to Azithromycin.¹⁹

Global antimicrobial resistances are the worldwide problems. Most of the policlinics are still using fluoroquinolones although it is not working as well.^{20, 21} Regarding to the strains, a high prevalence of *S. typhi* and *S. paratyphi*. A strains in the quinolone Nepal that showed resistance against nalidixic acid (MIC> 256 mcg/ml with a corresponding decreased susceptibility against fluoroquinolones such as ciprofloxacin (MIC>0.125 mcg/ml).^{22, 23}. Nowadays third generation cephalosporin are being used as if it were a first line agent for typhoid fever in many countries. Azalides are another class of antibiotics which have shown promise in the treatment of typhoid fever. Azithromycin is first line drug of azalides class. It has been found that Azithromycin reduces the clinical failures rate and duration of hospital

stay in comparison to fluoroquinolones and relapse rate in comparison to treatment of multidrug resistant typhoid fever.²⁴

In two tertiary care hospitals of Kathmandu Valley (Patan Hospital and Civil Hospital) Azithromycin (1000mg once a day for 5 days) is being prescribed for OPD and Inj Ceftriaxone (2 gm once a day) for the in patients of typhoid fever respectively on the base of evidence. Ceftriaxone is for in patients up to this point. The initial results of Azithromycin in enteric fever are reported to be encouraging. Studies comparing the efficacy of Azithromycin with Cefixime in adults and children with typhoid fever have reported to be safe and efficacious.^{25, 26}

Azithromycin

Azithromycin is an azalide antimicrobial, acts by inhibiting ribonucleic acid (RNA)dependent protein synthesis by binding to the receptor at the bacterial 50S ribosomal subunit. ²⁷ It is available in various dosages form like capsules, film-coated tablets and as well as powder for oral suspension.

Cefixime

Cefixime is an antibiotic useful to treat a wide variety of bacterial infections. It lies in third generation cephalosporin which only cure the bacterial infections not viral infections. Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness ²⁸

MATERIALS AND METHOD

The reference of *salmonella typhi* ATCC no. 14028 was obtained from Vega pharmaceuticals Pvt Ltd and other samples of *salmonella typhi* from patient's blood culture were taken from the three hospitals viz; Siddhi Memorial hospital, Summit hospital and Norvic hospital

Kirby Bauer Susceptibility Test Method:

The Kirby-Bauer test for antibiotic susceptibility (also called the disc diffusion) test is used to determine the resistance or sensitivity of aerobes or facultative anaerobes to specific chemicals, which can forward for the clinical practice. The zone of inhibition shows the efficacy of specific chemical towards the bacteria.

RESULT

Zone of inhibition shown by Cefixime and Azithromycin in *Salmonella typhi* isolates from different area.

						1
Concentration(npm)	0.25	0.5	4	8	32	128
eoneentration(ppin)	0.25	0.0	•	0	52	120
Vega	6mm	6mm	13mm	15mm	21mm	36mm
, ogu	omm	011111	1011111	1011111		2011111
Siddhi	6mm	6mm	13mm	15mm	21mm	35mm
Siddin	omm	omm	1511111	1011111	2111111	5511111
Norvic	6mm	6mm	13mm	14mm	20mm	36mm
	UIIIII	omm	1511111	1 711111	2011111	John
Summit	6mm	6mm	13mm	15mm	20mm	35mm
Summu	UIIII	UIIII	1,511111	1,JIIIII	2011111	JJIIII

Table 1; Zone of inhibition shown by different concentration of Cefixime

As shown in table, the zone of inhibition shown by Cefixime is almost same in all the isolates collected from different places.

	Table 2:	Zone of inhibition	shown by	different	concentration	of azithromyci	n
--	----------	--------------------	----------	-----------	---------------	----------------	---

Concentration(ppm)	0.25	0.5	4	8	32	128
Vega	6mm	6mm	8mm	9mm	12mm	26mm
Siddhi	6mm	6mm	7mm	8mm	11mm	25mm
Norvic	6mm	6mm	8mm	9mm	11mm	26mm
Summit	6mm	6mm	7mm	9mm	12mm	26mm

As shown in table no 2, the zone of inhibition shown by azithromycin is almost same in all the isolates collected from different places.



Figure 1: Concentration Vs Zone of inhibition (Vega pharmaceutical Pvt ltd)

 Table 3: Ratio of zone of inhibition shown by different concentration of cefixime and azithromycin

Sampling area	Concentration	0.25	0.5	4	8	32	128
Vega	Cefixime/azithr omycin	1	1	1.733	1.685	1.782	1.38

As comparing the ratio between Cefixime and Azithromycin, it showed that in concentration 0.25 ppm and 0.5 ppm, both drugs showed same zone of inhibition. On increasing the concentration in both drugs (4ppm, 8ppm, 32 ppm), it showed that zone of inhibition of Cefixime is increasing as compared to Azithromycin (1.63, 1.67, 1.75). However, the zone of inhibition decreased by 1.38 folds when concentration is increased to 128 ppm.



Figure 2: Concentration Vs Zone of inhibition (Siddhi Polyclinic)

Table 4:	Ratio of zone	of inhibition	shown	by different	concentration	of cefixime and
azithrom	nycin					

Sampling area	Concentration	0.25	0.5	4	8	32	128
Siddhi polyclinic	Cefixime / azithromycin	1	1	1.85	1.87	1.90	1.4

As comparing the ratio between Cefixime and Azithromycin, it showed that in concentration 0.25 ppm and 0.5 ppm, both drugs showed same zone of inhibition. On increasing the concentration in both drugs (4ppm, 8ppm, 32 ppm), it showed that zone of inhibition of Cefixime is increasing as compared to Azithromycin (1.85, 1.87, 1.90). However, the zone of inhibition decreased by 1.4 folds when concentration is increased to 128 ppm.



Figure 3: Concentration Vs Zone of inhibition (Norvic)

Table 5: Ratio of zone of inhibition shown by different concentration of ce	efixime and
azithromycin	

Sampling area	concentration	0.25	0.5	4	8	32	128
Norvic hospital	Cefixime/azithromycin	1	1	1.63	1.78	1.81	1.38

As comparing the ratio between cefixime and azithromycin, it showed that in concentration 0.25 ppm and 0.5 ppm, both drugs showed same zone of inhibition. On increasing the concentration in both drugs (4ppm, 8ppm, 32 ppm), it showed that zone of inhibition of Cefixime is increasing as compared to Azithromycin (1.63, 1.78, 1.81). However, the zone of inhibition decreased by 1.38 folds when concentration is increased to 128 ppm.



Figure 4: Concentration Vs Zone of inhibition (Summit hospital)

As presented in above table, the zone of inhibition of Cefixime is greater than the zone of inhibition shown by azithromycin in all sample isolated from different hospital in different concentration. The highest diameter of zone of inhibition of azithromycin (23 mm) and Cefixime (37 mm) was seen in 128 ppm concentration of each antibiotic. The lowest diameter of zone of inhibition of Azithromycin (6mm) and Cefixime (6mm) was seen in 4 ppm and 0.5 ppm concentration of azithromycin and Cefixime respectively.

Table 6: Ratio of zone of inhibition shown by different concentration of Cefixime and Azithromycin

Sampling area	Concentration	0.25	0.5	4	8	32	128
Summit hospital	Cefixime / azithromycin	1	1	1.85	1.67	1.67	1.34

As comparing the ratio between Cefixime and Azithromycin, it showed that in concentration 0.25 ppm and 0.5 ppm, both drugs showed same zone of inhibition. On increasing the concentration in both drugs (4ppm), it showed that zone of inhibition of Cefixime is increasing as compared to Azithromycin (1.85). However, the zone of inhibition is same when concentration is increased to 8 ppm and 32ppm and get decreased by 1.34 folds when concentration is increased to 128 ppm.



Figure 5: Comparison of Zone of inhibition shown by Azithromycin and Cefixime

As shown in fig 5 the zone of inhibition shown by both Azithromycin and Cefixime is same at low concentration (0.25ppm, 0.5ppm) but with increasing in concentration there is increase

in difference in zone of inhibition shown by them. The zone of inhibition shown by Cefixime is greater in high concentration as compared to zone of inhibition shown by Azithromycin

DISCUSSION

This study was carried out to compare the antimicrobial efficacy of Azithromycin and Cefixime against *Salmonella typhi* isolate collected from different hospitals and to know either the isolates are sensitive or resistance to them.

The samples were collected from 3 different hospitals and one standard sample of *Salmonella typhi* ATCC no.14028 was collected from Vega pharmaceuticals. The standard Azithromycin and Cefixime was brought from Vega pharmaceuticals and Vijayadeep pharmaceuticals respectively. The antimicrobial activity of Azithromycin and Cefixime were tested against the collected sample and result were compared.

Since the load variation of bacteria and standard of drugs are not same with other research, we cannot compare our data with other research data done by in vitro method. As comparing to the in vitro activity with in vivo activity, it shows the similar type of result. Comparing the efficacy of Azithromycin in the treatment of childhood for a period of one year from January 2011 to December 2011, the clinical cure rate was 87% in azithromycin group and 93% in cefixime group.²⁹ An in vivo study shows that Azithromycin and Cefixime up to 7 days for the treatment of uncomplicated typhoid fever, a total of 31 (91%) of the 34 patients treated with Azithromycin and 29 (97%) of the 30 patient treated with Cefixime were cured.³⁰

An open label, non-comparative study, which evaluated the efficacy and safety of Azithromycin for the treatment of uncomplicated enteric fever, found that azithromycin cured 93% of the subjects whereas the Cefixime cured 100% of the subjects.³¹

Azithromycin was said to have been effective in 92.4% of the 1039 reports which included an opinion about effectiveness whereas Cefixime was said to have been effective in 94.29% of the 1039.³²

CONCLUSION

Salmonella typhi is more sensitive to Cefixime than Azithromycin. From the above data it can be concluded that for the treatment of typhoid fever Cefixime is more effective than the Azithromycin. The certain stamps the *Salmonella typhi* shows resistance. So, regular monitoring of emergence of resistance is highly recommended and specific antibiotic should be identified after antibiotic susceptibility test and results for the effective management of disease caused by *Salmonella typhi*.

ACKNOWLEDGMENTS

We would like to acknowledge Pro. Dr. Dharma Prasad Khanal (visiting professor, Mewar University, Rajasthan,India), Krishna Govind Prajapati, Sarad Pudasaini, Sharmila Joshi, Alina Shrestha, Puja Adhikari, Ranjit Singh Mahato, Vega pharmaceuticals Pvt Ltd, Siddhi Memorial hospital, Summit hospital and Norvic hospital Pvt. Ltd for their magnanimous support on the study.

REFERENCE:

- 1. Crump JA, Mintz ED. Global trends in typhoid and paratyphoid fever. *Clin Infect Dis* 2010; 50:241–6.
- 2. Crump JA, Youssef FG, Luby SP, et al. Estimating the incidence of typhoid fever and other febrile illnesses in developing countries. *Emerg Infect Dis* 2003; 9:539–44.
- 3. Buckle GC, Walker CLF, Black RE. Typhoid fever and paratyphoid fever: systematic review to estimate global morbidity and mortality for 2010. *J Glob Health* 2012; 2:010401.
- 4. Mogasale V, Maskery B, Ochiai RL, et al. Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk- factor adjustment. *Lancet Glob Health*,2014; 2: 570–80.
- 5. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; 380:2095–128.
- 6. WHO. The global burden of typhoid fever. *Bull World health Organization*, 2004;82(5):346-53.
- 7. The World Bank. World Bank Open Data: free and open access to data about development in countries around the globe. http://data.worldbank.org. Accessed 10 February 2014.
- 8. Maskey AP, Basnyat B, Thwaites GE, Campbell JI, Farrar JJ, Zimmerman MD. Emerging trends in enteric fever in Nepal: 9124 cases confirmed by blood culture 1993–2003. *Trans R SocTrop Med Hyg* 2008; 102: 91–95.
- 9. Karkey A, Aryjal A, Basnyat B, Baker S. Kathmandu, Nepal: still an enteric fever capital of the world. *J Infect Dev Ctries* 2008; 2: 461–65.
- 10. WHO. Background document: the diagnosis, treatment and prevention of typhoid fever. *Geneva: World Health Organization*, 2003: 19–23.
- 11. Parry CM, Vinh H, Chinh NT, et al. The influence of reduced susceptibility to fl uoroquinolones in Salmonella enteric serova typhi on the clinical response to ofloxacin therapy. *PLoSNegl Trop Dis 2011*; 5: e1163.
- 12. Yanagi D, de Vries GC, Rahardjo D, Alimsardiono L, Warito EB and De I,et al. Emergence of fluoroquinolone resistant strains of Salmonella enterica in Surabaya, Indonesia. *DiagnMicrobiol Infect Dis.* 2009; 64 (4): 422-26.
- 13. Aggarwal A, Ghosh A, Gomber S, Mitra M and Parikh AO. Efficacy and safety of azithromycin for uncomplicated typhoid fever: an open label non-comparative study. *Indian Pediatr* 2011; 48 (11). 553-6.
- 14. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. *NEnglJMed*2002; 347:1770-82.

- 15. Erslev A, Wintrobe MM. Detection and Prevention of Drug induced Blood dyscrasias. J Amer Med Assoc. 1962;181:114-9.
- 16. Dastur FD. Salmonellosis in API Text Book of Medicine, 6th edn. 1999: 37-40.
- 17. Butt T, Rifat NA, Abid M, Zaidi S. Ciprofloxacin treatment failure in typhoid fever cases, Pakistan. *EmergInfec Dis.* 2003;9(12):1621-2.
- 18. Thapa and Khanal. Treatment of Enteric Fever and Undifferentiated Febrile Illness in Nepal: A Review. *IJPSR*, (2017)vol 8 (7), 2815-18.
- 19. Thapa and Khanal. Efficacy of Azithromycin and Ceftriaxone for the treatment of Enteric Fever in two Tertiary Care Hospitals of Kathmandu, Nepal. J. Global Trends in *Pharmaceutical Sci*, 2019, 10(3): 6362-63-67.
- 20. Wong VK, Baker S, Pickard DJ, et al. Phylogeographical analysis of the dominant multidrugresistant H58 clade of Salmonella typhi identifies inter- and intracon- tinental transmission events. *Nat Genet* 2015; 47:632–9.
- 21. Baker S, Duy PT, Nga TV, et al. Fitness benefits in fluoroquinolone-resistant Salmonella typhi in the absence of antimicrobial pressure.*Elife* 2013; 2:e01229.
- 22. Pham Thanh D, Karkey A, Dongol S, et al. A novel ciprofloxacin-resistant sub- clade of H58 Salmonella typhi is associated with fluoroquinolone treatment failure.*Elife* 2016; 5:e14003
- 23. Maskey AP, Basnyat B, Thwaites GE, Campbell JI, Farrar JJ, Zimmerman MD. Emerging trends in enteric fever in Nepal: 9124 cases confirmed by blood culture 1993–2003. *Trans R Soc Trop Med Hyg* 2008; 102: 91–95.
- 24. Parry CM, Thuy CT, Dongol S, et al. Suitable disk antimicrobial susceptibility breakpoints defining Salmonella entericaserovarTyphi isolates with reduced susceptibility to fluoroquinolones. *Antimicrob Agents Chemother* 2010; 54: 5201–08.
- 25. Dheeraj Shah. Role of Azithromycin in enteric fever cochrane collection. *Indian pediatrics* 2009; 46: 56-52.
- 26. Kundu R, Ganguly N, Ghosh TK, Yewale VN, Shah RC, Shah NK; IAP Task Force. IAP Task Force Report: Management of enteric fever in children. *Indian Pediatr*. 2006;43:884-887.
- 27. Piscitelli S, Danziger LHRK. Clarithromycin and azithromycin: new macrolide antibiotics. *Clin Pharm.* 1992;11:137–52.
- 28. Systematic review and meta-analysis on efficacy of cefixime for treating gonococcalinfections. Tanvir SB, Qasim SSB, Int J Health Sci (Qassim). Dis.2018 Sep.
- 29. B begum MA Haque M S Ahmed comparison between azithromycin and cefixime in the treatment of typhoid fever in children. *Mymensingh medical journal* 2014;3: 441-8

- Azithromycin versus cefxime for the treatment of uncomplicated typhoid fever in children. Robert W, Frenckjr.Isabella N, Yehi S. *Clinical infectious disease*2015; vol.31, issue 5: 1134-1138.
- 31. Upadhyay. R, Nadka. M, Banka. N.H, API recommendations for the management of typhoid fever. *Journal of the association of physicians of India*. 2015 Vol 63.
- 32. L.v.wilton, G.L. Pearce and R. D. Mann, Acomparision of ciprofloxacin, norfloxacin, azithromycin and cefixime examined by observational cohort studies. *Br j clinpharmacol* 1996;41: 277-84.

Annex: I Photographs





Annex II: Procedure for Antimicrobial Susceptibility test

Preparation of Nutrient Agar (NA) media and subculture of bacteria

28 gram of NA was weighed and 1000ml of distilled water was added. Then it was boiled in conical flask with occasional stirring. It was sterilized then in autoclave at 121 $^{\circ}$ C and 15 lb pressure for 15 minutes. It was then poured in the sterilized petriplate and left for sometimes to cool down it. Then after the solidification of the media the bacteria was subcultured with the help of the sterilized loop by streak method and then incubated for 24 hours at 37 $^{\circ}$ C.

Preparation of Nutrient Broth (NB) media and subculture of bacteria

0.312 gm of NB was weighed and 25 ml of water was added in a test tube. Then it was sterilized in autoclave at 121 °c and 15 lb. pressure for 15 minutes and left to cool it. Then bacteria were inoculated in the media and incubated for 4 hours and compared its turbidity with McFarland (0.5).

Preparation of McFarland tube

1% H_2SO_4 (9.95 ml) and 1% $BaCl_2$. H_2O (0.05 ml) was mixed in a test tube. It had a cloudy look.

Preparation of Muller-Hilton Agar (MHA) media

38 gram of MHA was weighed and kept in a conical flask and then 1000ml of water was added. Then it was boiled in the burner and sterilized in the autoclave at 121 $^{\circ}$ c and 15 lb pressure for 15 minutes. Then it was poured in the petri plate and cooled down to the room temperature.

Preparation of antibiotic stock solutions

0.25-128 mg/l dilution range for both azithromycin and cefixime was chosen.
Stock solution was prepared by using the formula
100/p x V x C=W
Where p= potency given by manufacturer
V= volume required
C= final concentration of solution and
W= Weight of antibiotic in mg to be dissolved in volume V.
For cefixime

W= 1000/1023.7 x 25 x 10 = 244.21 mg

For azithromycin

W= 1000/996.8 x 25 x 10 = 250.802 mg

244.21 mg of cefixime and 250.802 mg of azithromycin dissolved in 25 ml of saturated sodium bicarbonate solution and ethanol(70%) respectively = 10,000 mg/l stock solution.

prepared

1 ml of 10,000 mg/l +9 ml distilled water = 1000 mg/l

 $100 \ \mu l \text{ of } 10,000 \ mg/l + 9.9 \ ml \ diluent = 100 \ mg/l$

Preparation of antibiotic dilution range

Selected concentration: 128 ppm, 32 ppm, 8 ppm, 4 ppm, 1, 0.5 ppm, 0.25 ppm

For 128 ppm and 32 ppm concentration, 256µl and 32µl was dispensed in beaker having 20 ml sterilized water respectively from the 10,000 mg/l stock solution.

For 8 ppm and 4 ppm concentration, 160µl and 80µl was dispensed in beaker having 20 ml sterilized water respectively from the 1000mg/l stock solution.

For 0.5 ppm and 0.25 ppm concentration, 100µl and 50 µl was dispensed in beaker having 20 ml sterilized water respectively from 100 mg/l stock solution.

Subculture of bacteria

The two well having diameter 6mm was made in upper and lower part of MHA media and the bacteria from NB media (whose turbidity was same as the McFarland 0.5) were sub cultured in MHA media with cotton swab by spread plate method. Then it was left for sometimes and 70 μ l of different concentration of cefixime and azithromycin was placed in well of upper and lower part of MHA respectively of each 24 petri plates. These plates were then incubated at 37°C for 24 hours. Then the zones of inhibition shown by different concentration were measured.